

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived		
	Human ALK-1 (Asp22 - Gln118) Accession # P37023.2	IEGRID	Human IgG ₁ (Pro100 - Lys330)
	N-terminus		C-terminus

N-terminal Sequence Analysis	Asp22
Structure / Form	Disulfide-linked homodimer
Predicted Molecular Mass	37.3 kDa (monomer)

SPECIFICATIONS

SDS-PAGE	50-55 kDa, reducing conditions
Activity	Measured by its ability to inhibit BMP-9-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. David, L. <i>et al.</i> (2007) Blood 109 :1953. The ED ₅₀ for this effect is 3-12 ng/mL in the presence of 2 ng/mL of rhBMP-9.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 100 µg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Transforming Growth Factor beta (TGF-β) superfamily ligands exert their biological activities via binding to heteromeric receptor complexes of two types (I and II) of serine/threonine kinases. Type II receptors are constitutively active kinases that phosphorylate type I receptors upon ligand binding. In turn, activated type I kinases phosphorylate downstream signaling molecules including the various smads. Transmembrane proteoglycans, including the type III receptor (betaglycan) and endoglin, can bind and present some of the TGF-β superfamily ligands to type I and II receptor complexes and enhance their cellular responses. Seven type I receptors (also termed activin receptor-like kinase (ALK)) and five type II receptors have been isolated from mammals. ALK-2, -3, -4, -5, and -6 are also known as Activin R1A, BMPR-1A, Activin R1B, TGF-β R1, and BMPR-1B, respectively, reflecting their ligand preferences. Evidence suggests that TGF-β1, TGF-β3 and an unknown ligand present in serum can activate chimeric ALK-1. ALK-1 shares with other type I receptors a cysteine-rich domain with conserved cysteine spacing in the extracellular region, and a glycine- and serine-rich domain (the GS domain) preceding the kinase domain. ALK-1 is expressed highly in endothelial cells and other highly vascularized tissues. The expression patterns of ALK-1 parallels that of endoglin. Mutations in ALK-1 as well as in endoglin are associated with hereditary hemorrhagic telangiectasia (HHT), suggesting a critical role for ALK-1 in the control of blood vessel development or repair. Human and mouse ALK-1 share approximately 71% amino acid sequence identity in their extracellular regions.

References:

1. ten Dijke, P. *et al.* (1993) Oncogene **8**:2879.
2. ten Dijke, P. *et al.* (1994) Science **264**:101.
3. Lux, A. *et al.* (1999) J. Biol. Chem. **274**:9984.